These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30041608)

  • 21. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study.
    Arnold JJ; Markey CM; Kurstjens NP; Guymer RH
    BMC Ophthalmol; 2016 Mar; 16():31. PubMed ID: 27009515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TYPE 2 (SUBRETINAL) NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION ASSOCIATED WITH PURE RETICULAR PSEUDODRUSEN PHENOTYPE.
    Naysan J; Jung JJ; Dansingani KK; Balaratnasingam C; Freund KB
    Retina; 2016 Mar; 36(3):449-57. PubMed ID: 26383711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. OUTCOMES OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR THREE OR MORE YEARS: A Review of Current Outcomes.
    Qin VL; Young J; Silva FQ; Conti FF; Singh RP
    Retina; 2018 Aug; 38(8):1500-1508. PubMed ID: 28671895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy.
    Cho M; Barbazetto IA; Freund KB
    Am J Ophthalmol; 2009 Jul; 148(1):70-8.e1. PubMed ID: 19403115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Antiangiogenic therapy of neovascular age-related macular degeneration].
    Fayzrakhmanov RR; Voropaev VY; Sukhanova AV; Shatalova EO
    Vestn Oftalmol; 2021; 137(1):83-93. PubMed ID: 33610155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conbercept for Treatment of Neovascular Age-Related Macular Degeneration and Visual Impairment due to Diabetic Macular Edema or Pathologic Myopia Choroidal Neovascularization: A Systematic Review and Meta-Analysis.
    Zhou P; Zheng S; Wang E; Men P; Zhai S
    Front Pharmacol; 2021; 12():696201. PubMed ID: 34712132
    [No Abstract]   [Full Text] [Related]  

  • 27. Anti-Vascular Endothelial Growth Factor Drug Conbercept-Loaded Peptide Hydrogel Reduced Angiogenesis in the Neovascular Age-Related Macular Degeneration.
    Fan W; Li S; Tao J; Yu C; Sun M; Xie Z; Wu X; Ge L; Wu Y; Liu Y
    J Biomed Nanotechnol; 2022 Jan; 18(1):277-287. PubMed ID: 35180922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neovascular age-related macular degeneration treated with ranibizumab or aflibercept in the same large clinical setting: visual outcome and number of injections.
    Rasmussen A; Sander B; Larsen M; Brandi S; Fuchs J; Hansen LH; Lund-Andersen H
    Acta Ophthalmol; 2017 Mar; 95(2):128-132. PubMed ID: 27535819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration.
    Matsumoto H; Hiroe T; Morimoto M; Mimura K; Ito A; Akiyama H
    Jpn J Ophthalmol; 2018 Mar; 62(2):144-150. PubMed ID: 29411171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results.
    Berg K; Hadzalic E; Gjertsen I; Forsaa V; Berger LH; Kinge B; Henschien H; Fossen K; Markovic S; Pedersen TR; Sandvik L; Bragadóttir R
    Ophthalmology; 2016 Jan; 123(1):51-9. PubMed ID: 26477842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Anti-VEGF therapy resistance in neovascular age-related macular degeneration].
    Budzinskaya MV; Plyukhova AA; Sorokin PA
    Vestn Oftalmol; 2017; 133(4):103-108. PubMed ID: 28980574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SWITCHING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FROM BEVACIZUMAB TO RANIBIZUMAB: Who is Likely to Benefit From the Switch?
    Moisseiev E; Katz G; Moisseiev J; Loewenstein A; Goldstein M; Lomnicky Y; Abend Y; Treister G; Goldenberg D; Levkovitch-Verbin H
    Retina; 2015 Jul; 35(7):1323-30. PubMed ID: 26102434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baseline Predictors for Good Versus Poor Visual Outcomes in the Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Therapy.
    Chae B; Jung JJ; Mrejen S; Gallego-Pinazo R; Yannuzzi NA; Patel SN; Chen CY; Marsiglia M; Boddu S; Freund KB
    Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5040-7. PubMed ID: 26237196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment
    Witkin AJ; Rayess N; Garg SJ; Maguire JI; Storey P; Kaiser RS; Hsu J; Vander JF; Ho AC
    Semin Ophthalmol; 2017; 32(3):309-315. PubMed ID: 26337539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-VEGF therapy in symptomatic peripheral exudative hemorrhagic chorioretinopathy (PEHCR) involving the macula.
    Seibel I; Hager A; Duncker T; Riechardt AI; Nürnberg D; Klein JP; Rehak M; Joussen AM
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):653-9. PubMed ID: 26148802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration.
    Braimah IZ; Agarwal K; Mansour A; Chhablani J;
    Br J Ophthalmol; 2018 Jan; 102(1):91-96. PubMed ID: 28596286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Wet age related macular degeneration management and follow-up.
    Alexandru MR; Alexandra NM
    Rom J Ophthalmol; 2016; 60(1):9-13. PubMed ID: 27220225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Anti-VEGF therapy for neovascular age-related macular degeneration: causes of incomplete response].
    Zaytseva OV; Neroeva NV; Okhotsimskaya TD; Bobykin EV
    Vestn Oftalmol; 2021; 137(5):152-159. PubMed ID: 34726870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retinal Ganglion Cell Layer Change in Patients Treated With Anti-Vascular Endothelial Growth Factor for Neovascular Age-related Macular Degeneration.
    Beck M; Munk MR; Ebneter A; Wolf S; Zinkernagel MS
    Am J Ophthalmol; 2016 Jul; 167():10-7. PubMed ID: 27084000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed Ranibizumab.
    Gonzalez-Buendia L; Delgado-Tirado S; Sanabria MR; Fernandez I; Coco RM
    BMC Ophthalmol; 2017 Aug; 17(1):147. PubMed ID: 28821236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.